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Summary 
Background. Gram negative bacterial infections (GNBI) are a major cause of morbidity and 
mortality in Hematopoietic Stem Cell Transplant (HSCT) and updated epidemiological 
investigation is advisable.  
 
Methods. We prospectively evaluated the epidemiology of pre-engraftment GNBI in 1,118 
allogeneic HSCT (allo-HSCT) and 1,625 autologous HSCT (auto-HSCT) among 54 transplant 
centers during 2014 (SIGNB-GITMO-AMCLI study). Using logistic regression methods we 
identified risk factors for GNBI and evaluated the impact of GNBI on the 4-month overall-survival 
after transplant. SIGNB-GITMO-AMCLI is registered with ClinicalTrials.gov, number 
NCT02088840. 
 
Findings The cumulative incidence of GNBIs was 18.6% in allo-HSCT and 10% in auto-HSCT. E. 
coli, K. pneumoniae and P. aeruginosa were the most common isolates. By multivariate analysis 
variables associated with pre-engraftment GNBI were a diagnosis of acute leukemia, a transplant 
from  HLA-mismatched donor  and from cord-blood,  older age and duration of severe neutropenia 
in  allo-HSCT, and  a diagnosis of lymphoma, older age and no antibacterial prophylaxis in auto-
HSCT. A pre-transplant infection by a resistant pathogen was significantly associated to an 
increased risk of post-transplant infection by the same microorganism in allo-HSCT.  Colonization 
by resistant Gram-negative bacteria was significantly associated to an increased risk of pre-
engraftment infection by the same pathogen in both transplant procedures. GNBIs were  
independently associated to increased mortality at 4-months from transplant both in allo-HSCT (HR 
2.08, 95% CI 1.43-3.04; p=.0001) and auto-HSCT (HR 2.52, 95% CI 1.28-4.99; p=.008).  
 
Interpretation. Pre-engraftment GNBIs are a major cause of morbidity and mortality in auto-
HSCT and allo-HSCT. Previous infectious history and colonization monitoring represent major 
indicators of GNBI.   
 
Funding: Pfizer Italia 
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Introduction 
Gram negative bacterial infections (GNBI) are a leading cause of morbidity and mortality in 
hematologic patients including those submitted to Hematopoietic Stem Cell Transplant (HSCT) (1-
9). A challenging aspect is represented by the continuous evolution of the incidence, susceptibility 
pattern to antibiotics and prognosis due to the change of the transplant populations,  the global 
epidemiology of bacterial infections and  the antimicrobial strategies. Therefore, updated 
epidemiological investigation in this high risk population is advisable.  
Because of the poor outcomes associated with GNBIs in transplant patients, there is much 
interest in the identification of risk and prognostic factors which may help to determine  tailored 
treatment strategies (5, 8,9). Risk factors for bacterial infections have been evaluated extensively in 
HSCT patients, but there are few studies describing specific variables related to outcome (4,6,7,10).   
To assess the current incidence, risk and prognostic factors of pre engraftment GNBIs in 
allogeneic and autologous HSCT patients, data of patients undergoing allogeneic HSCT (allo-
HSCT) and autologous HSCT (auto-HSCT) during 2014 were prospectively registered.  These data 
provide the basis for promoting direct efforts in risk stratification, prevention and management of 
GNBIs in the HSCT population. 
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Methods 
Study design. GITMO-AMCLI Severe Infections by Gram Negative Bacteria (SIGNB) study was a 
prospective epidemiological survey done in 54 transplant Centres in Italy along a period of one 
year: 1 January –31 December 2014. It was sponsored by the Italian Transplantation Network 
(Gruppo Italiano Trapianto di Midollo Osseo, GITMO) and the Italian Association of Clinical 
Microbiology (Associazione Microbiologi Clinici Italiani , AMCLI). Study start time could differ 
among Centres but all consecutive transplants were enrolled. Data collection of each case was 
interrupted 4 months after transplant, therefore the study end date was 30 April 2015. Data were 
entered into electronic case report forms and all reported results derive from the database locked at 
December  31, 2015. The results of this study were reported according to the STROBE 
(STrengthening the Reporting of OBservational studies in Epidemiology) statement (11). The study 
was approved by the ethical committee of each participating centre and informed consent was 
obtained from the patients.  
Data collection. Variables included patients characteristics, diagnosis and phase of the underlying 
disease,  prior auto-HSCT or allo-HSCT, neutropenia during the 30 days before transplant, GNBIs 
documented  within the three months before transplant, stem cell donor, stem cell source, 
pretransplant conditioning regimen, the use of  “in vivo” T cell depletion with antithymocyte 
globulin (ATG) or manipulation ex vivo, antibacterial prophylaxis during the engraftment period, 
colonization by resistant Gram-negative bacteria at the pre-transplant screening and during 
engraftment, development of grade II-IV mucositis, duration of pre-engraftment neutropenia, 
development of grade II-IV acute Graft versus Host Disease (GvHD) before engraftment, 
microbiologically documented bacterial, fungal and viral diseases and clinically documented 
infections before engraftment, survival at 4 months from transplant and cause of death. Information 
pertaining to the GNBIs included timing after HSCT, in vitro susceptibility data, and site of 
infection. Data on antibacterial treatments given at onset of febrile/infectious episode before 
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knowing the microbiological results (first line treatment) and any subsequent empirical or 
microbiologically driven modification of the treatment (second line treatment) in the cases of GNBI 
were also collected, however, they were not considered in the present paper but will be the subject 
of  a following  analysis.  
Definition of infection and colonization. Cases of GNBI were defined as isolation of Gram 
negative bacteria from blood, other normally sterile body sites and from non-sterile body sites 
associated to signs of infection being a simple colonization excluded. The clinical and 
microbiological data reported to define cases of GNBI were reviewed to determine the reliability of 
the diagnosis.   Onset of GNBI was defined as the day when  the first positive  culture was taken.  
For each GNBI isolate in vitro susceptibility data were collected, including sensitivity or 
nonsensitivity to third generation cephalosporins (ceph-S or ceph-NS) and sensitivity or 
nonsensitivity to carbapenems (imipenem and/or meropenem and/or ertapenem) (carba-S or carba-
NS) for enterobacteria, (defined as a minimum inhibitory concentration, MIC,  for imipenem and/or 
meropenem and/or ertapenem higher than 1 mg/L) and multi-drug-resistance (MDR) for Gram-
negative non-fermenters (defined as resistance to three or more antimicrobial groups among 
piperacillin-tazobactam, ceftazidime,  fluoroquinolones, aminoglycosides and carbapenems).  
The investigators were also asked to specify whether a surveillance of colonization by resistant 
bacteria (ceph-NS and carba-NS enterobacteria, and MDR non-fermenters), by culture of 
rectal/perianal swabs, was routinely performed at their center before and after transplant, and 
reported the cases of colonization documented in the 3 months before transplant and during the 
engraftment period after transplant. Therefore, for the colonization analysis, we excluded the 
population of the centers that never performed a screening for colonization by the above resistant 
pathogens.  
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Analyses. All the analyses were made separately for auto-HSCT and allo-HSCT patients. 
The pre engraftment cumulative incidence of GNBIs was calculated accounting for the competing 
risks of infection-free death. Cumulative incidence of GNBIs was calculated for any type and status 
of the underlying disease, any type of stem cell donor, stem cell source and pretransplant 
conditioning, history of GNBI before transplant, antibacterial prophylaxis, a-GVHD. All factors 
were evaluated in multivariate models to control potential confounders.  
Survival analyses were performed according to the above variables.  A death was attributed 
to the GNBI in patients who failed to respond to therapy (i.e., who had stable disease or disease 
progression) and in patients with a partial response to therapy who died as the result of an acute 
event involving any of the sites of infection and in the absence of other causes thought to have 
primarily contributed to death. Probability of 4 months survival from HSCT was calculated with 
Kaplan–Meier estimate, log-rank test was applied for univariate analysis and two-sided p-values 
0.05 were considered to represent statistical significance. Multivariate analyses were performed 
with Cox proportional hazards regression model. In this model variables related to GNBI and  a-
GvHD were considered as time-dependent covariates in order to evaluate their effect only in the 
period following their onset.  All significant variables in univariate analysis were included in 
multivariate analysis; final models were also evaluated with backward and stepwise function. In all, 
95% confidence intervals  were reported for the main summary statistics and all statistical 
comparisons were based on two-tailed tests. Statistical analyses were done with SAS software 
version 9.4 and all comparisons are two-sided with a nominal significance level of 5%. 
GITMO-AMCLI-SIGNB is registered with Clinicaltrials.gov, number NCT02088840 
 
Role of the funding source. The study was sponsored  by the GITMO and AMCLI. An unrestricted 
grant was provided by Pfizer Italia to support the study. The funding sources had no role in 
identifying statements, synthesizing results, or preparing the manuscript, or in the decision to 
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submit the manuscript for publication. The decision to submit for publication was jointly taken by 
all contributors. 
Results 
Allogeneic HSCT  
Patient Characteristics.  
Overall 1,118 allo-HSCTs from 44 transplant centers were included in the study. Of these 
transplants  1013 were first and 105 second allo-HSCT, and 219 (19.6%) had been preceded by an 
auto-HSCT. The median number of transplants enrolled in the study among the 44 centres was 20 
(range 2- 105 transplants). Demographics and patient characteristics at transplant are shown in 
Table 1.  
Pre engraftment infections and details on GNBIs 
The rates of bacterial infections, fungal infections and end organ viral diseases documented 
before engraftment are detailed in Table 2.  
Overall, 157 GNBIs were documented in 148 of 1118 allo-HSCTs (13.2%) before 
engraftment (9 patients developed two distinct GNBIs by different bacterial species). Out of 157 
isolates, 149 (94.9%), 7 (4.4%) and 1(0.6%) were isolated from blood, urinary tract and skin 
(subcutaneous abscess), respectively. The rate of GNBIs by transplant centre ranged from 0% to 
39.3% (median 11.8%). The median rate of GNBI accounted for 11.1% and 13.3%  (p=0.8) in 
centers with lower (< 20 transplants)  and higher (>20 transplants) transplant activity, respectively. 
Escherichia coli was the most common Gram-negative pathogen (78 cases, 49.7%), followed by 
Klebsiella pneumoniae (32 cases, 20.4%) and Pseudomonas aeruginosa (23 cases, 14.6%).   
The susceptibility pattern of the isolates is detailed in table 3. Ceph-NS/carba-S and ceph-
NS/carba-NS was documented in 38.5% and 1.3% of E. coli, respectively, and in 25% and 53.1% of 
K. pneumoniae, respectively. MDR was documented in 36.4% of P. aeruginosa.  
Risk factors for GNBI in allo-HSCT recipients 
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The cumulative incidence of GNBIs at 30 days from transplant was 18.6% (95% Confidence 
Interval 13.7 – 24 %) (figure 1A).  GNBI free pre-engraftment death occurred in 25 (2.2%) cases. 
The risk of GNBI according to demographics, underlying disease and transplant variables are 
detailed in table 4. By multivariate analysis variables associated with pre engraftment GNBI were 
acute leukemia, a transplant from  HLA mismatched donor (both related and unrelated) and from 
cord blood,  older age and duration of severe (<100 PMN/cmm) neutropenia.  
Risk of GNBI according to pre-transplant infection and colonization 
A pre-transplant infection by one or more Gram-negative pathogens (88 isolates) was 
reported in 84 (7.5%) patients (ceph-S E.coli, 17 cases; ceph-NS/carba-S E.coli, 17 cases; ceph-S 
K.pneumoniae, 4 cases; ceph-NS/carba-S K.pneumoniae, 9 cases; carba-NS K.pneumoniae, 6 cases; 
non-MDR P.aeruginosa, 11 cases; MDR P.aeruginosa, 4 cases; Enterobacter cloacae complex, 6 
cases; other pathogens, 14 cases). In 16 of these 84 patients (19%) an infection by the same species 
with the same susceptibility phenotype was documented after a median of 7 days (range 1-25 days) 
after transplant (ceph-S E. coli, 1 case; ceph-NS E. coli, 5 cases; ceph-NS K. pneumoniae, 2 cases; 
carba-NS K. pneumoniae, 4 cases; Enterobacter cloacae complex, 1 case; non-MDR P. aeruginosa, 
3 cases). A significantly increased risk of pre-engraftment infection by the same species with the 
same susceptibility phenotype was documented in patients with a pre transplant infection by ceph-
NS/carba-S E. coli, carba-NS K. pneumoniae and non-MDR P. aeruginosa.  On the contrary pre-
transplant infection by ceph-S E.coli did not represent a risk for a post-transplant infection by the 
same pathogen (figure 2).   
A colonization by resistant Gram-negative bacteria was always associated to a significantly 
increased risk of pre-engraftment infection by the same pathogen. In particular, a high probability of 
a pre-engraftment infection by the same colonizing species was observed for carba-NS K. 
pneumoniae (32.5% in colonized vs. 0.8% in non-colonized, p<0.0001) and MDR P. aeruginosa 
(28.6% in colonized vs. 0.6% in non-colonized, p<0.0001) (figure 3).  
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Survival 
The overall survival (OS) of the entire population at 4 months from transplant was 86.3 % 
(95% CI 84.3 – 88.4%). In multivariate analysis, acute leukemia, a previous auto HSCT, a disease 
not in complete remission at the time of transplant, older age, prolonged pre engraftment 
neutropenia,  acute-GVHD, and pre engraftment GNBI (Hazard ratio 2.08, 95% CI 1.43-3.04; 
p=.0001) were factors independently associated to increased mortality (Table 5).  
The mortality rate at 30 days from the diagnosis of GNBI was 13.5% (25 of 148 patients) 
and in 96% of cases (24 of 25) the infection was considered the primary cause of death.  Of 46 
patients who died before engraftment, the cause of death was a GNBI in 18 (39.1%) cases.  
Probability of survival at 4 months from transplant in 970 patients who did not develop any 
GNBI was 88.4%, as compared to 80.4% in 46 patients with ceph-S E. coli infection (p=0.11), 
86.7% in 30 patients with ceph-NS E. coli infection (p=0.72), 43.8% in 16 patients with carba-NS 
K. pneumoniae infection (p<.0001), 64.3% in 14 patients with non-MDR P. aeruginosa infection 
(p=0.003) and 25% in 8 patients with MDR-P. aeruginosa infection (p<.0001) (Figure 4).   
 
Autologous HSCT  
Patient Characteristics.  
Overall 1,625 auto-HSCTs from 52 transplant centers were included in the study. Of these 
transplants, 1281 were first and 344 second auto-HSCT. The median number of transplants enrolled 
in the study among the 52 centres was 23 (range 4 - 101 transplants). Demographics and patient 
characteristics at transplant are shown in Table 1.  
Pre engraftment infections and details on GNBIs 
The rates of bacterial infections, fungal infections and end organ viral diseases documented 
before engraftment are detailed in Table 2.  
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Overall, 162 GNBIs were documented in 157 of 1,625 auto-HSCTs (9.7%) before 
engraftment (5 patients developed two distinct GNBIs by different bacterial species). Out of 162 
isolates, 151 (94.9%), 6 (3.7%), 4 (2.5%) and 1 (0.6%) were isolated from blood, urinary tract, 
intestinal tract and skin (subcutaneous abscess), respectively. The rate of GNBIs by transplant 
center ranged from 0% to 33.3% (median 7.6%). The median rate of GNBI accounted for 6.2% and 
8.8% (p=0.9) in centers with lower (< 23 transplants)  and higher (>23 transplants) transplant 
activity, respectively. E.coli was the most common Gram-negative pathogen (94 cases, 58.0%), 
followed by K. pneumoniae (25 cases, 15.4%), and P. aeruginosa (13 cases, 8.0%).  The 
susceptibility pattern of the isolates is detailed in table 3. Ceph-NS/carba-S and carba-NS phenotype 
was documented in 31.9% and 0% of E. coli, respectively, and in 40% and 28% of K. pneumoniae, 
respectively. MDR was documented in only one P. aeruginosa isolate (7.7%).  
Risk factors for GNBI in auto-HSCT recipients 
The cumulative incidence of GNBIs at 20 days from transplant was 10.0% (95% Confidence 
Interval 9 – 11%) (figure 1B).  GNBI free pre-engraftment death occurred in 6 (0.4%) cases. The 
risk of GNBI according to demographics, underlying disease and transplant variables are detailed in 
table 6. By multivariate analysis, variables associated with pre-engraftment GNBI were a diagnosis 
of lymphoma, older age and no antibacterial prophylaxis.  
Risk of GNBI by species according to pre-transplant infection and colonization 
A pre-transplant infection by a Gram-negative pathogen was reported in 39 cases (2.4%) 
(ceph-S E. coli, 7 cases; ceph-NS/carba-S E. coli, 5 cases; ceph-S K. pneumoniae, 7 cases, ceph-
NS/carba-S K. pneumoniae, 2 cases; carba-NS K.pneumoniae, 2 cases; Enterobacter cloacae 
complex 5 cases; other pathogens, 11 cases). In only 3 cases an infection by the same pathogen 
(ceph-S E. coli, ceph-S K. pneumoniae, carba-NS K. pneumoniae) was documented 2, 7 and 7 days 
after transplant, respectively.  
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Overall, 89/1307 (6.8%), 21/1307 (1.6%) , 21/1432 (1.5%) and 2/1307 (0.1%) evaluable 
patients were colonized by ceph-NS/carba-S E. coli, ceph-NS/carba-S K. pneumoniae, carba-NS K. 
pneumoniae and MDR P. aeruginosa, respectively. A significant correlation between colonization 
and pre-engraftment infection by the same species at 20 days from transplant was observed for 
ceph-NS/carba-S E. coli (10.5% in colonized vs. 4.5% in non-colonized, p=0.038), ceph-NS/carba-
S K. pneumoniae (20.4% in colonized vs. 0.3% in non-colonized, p<0.0001), and carba-NS K. 
pneumoniae (19.0% in colonized vs. 0.01% in non-colonized, p<0.0001).  
 
Survival 
The OS of the entire population at 4 months from auto-HSCT was 97% (95% CI 96.2 – 
97.9%). In multivariate analysis, a diagnosis of lymphoma, a prolonged  neutropenia during  the 
month preceding auto-HSCT, a disease not in complete remission at the time of transplant, 
prolonged pre engraftment neutropenia,  and pre engraftment GNBI (Hazard ratio 2.52, 95% CI 
1.28-4.99; p=.008) were factors independently associated to increased mortality (Table 7). The 
mortality rate at 30 days from the diagnosis of GNBI was 3.8% (6 of 157 patients) and in all cases 
the infection was considered the primary cause of death.  Of 11 patients who died before 
engraftment the cause of death was a GNBI in 4 (36.4%) cases. 
Probability of survival at 4 months from transplant in 1469 patients who did not develop any 
GNBI was 97.5%, as compared to 97.3% in 73 patients with ceph-S E. coli infection (p=0.91), 96% 
in 25 patients with ceph-NS/carba-S E. coli infection (p=0.63), 88.9% in 9 patients with ceph-S K. 
pneumoniae infection (p=0.09), 90% in 9 patients with ceph-NS/carba-S K. pneumoniae infection 
(p=0.14), 71.4% in 7 patients with carba-NS K. pneumoniae infections (p<.0001), and 76.9% in 13 
patients with non-MDR P. aeruginosa infection (p<.0001).   
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Discussion 
The increasing incidence of GNBIs resistant to antibiotics, including carbapenems, has 
become a public health problem of major concern worldwide (12-14). 
Antimicrobial resistance data from invasive isolates reported to the European Antimicrobial 
Resistance Surveillance Network (EARS-Net) by 30 European countries (trend analyses for the 
period 2012–2015) showed wide variations depending on the bacterial species, antimicrobial group 
and geographical region (14). A worrying situation was represented by the high and increasing 
resistance percentages reported from many parts of Europe. The observed increase in combined 
resistance to multiple antimicrobial groups, as well as the high proportion of isolates resistant to 
third-generation cephalosporins [generally related to an Extended Spectrum Beta Lactamase 
(ESBL) production], lead to an increased use of carbapenems, thus further favouring the emergence 
and spread of carbapenem-resistant enterobacteria, particularly among K. pneumoniae. Carbapenem 
resistance and MDR were also common in P. aeruginosa and Acinetobacter spp. In Italy, over the 
period 2012–2015, the rate of isolates resistant to third-generation cephalosporins  increased from 
26.3% to 30.1 % for E. coli and from 47.9% to 55.9% for K. pneumoniae, while carbapenem 
resistance increased from 29.1% to 33.5% for K. pneumoniae and remained stably <1% for E. coli. 
For P. aeruginosa carbapenem resistance was stable around 25% and MDR decreased from 23.7% 
in 2012 to 20% in 2015.   
Hematologic patients are considered at high risk for these severe infections, but only few 
information is specifically available regarding the incidence and prognostic factors of GNBI in this 
population of immunocompromised subjects, particularly those submitted to HSCT.  To our 
knowledge, only two multicenter studies, both from Italy, prospectively evaluated the epidemiology 
of GNBI in onco-hematologic populations, mainly in non-transplant patients, during the recent 
years, and confirmed the above resistance patterns observed in the general population (7,15). 
Literature data on the recent epidemiology of GNBIs specifically in HSCT populations are limited 
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to  retrospective, mainly single center, experiences.(16-24). These studies, while showing a variable 
rate of resistance patterns according to local epidemiology, patient age and type of transplant, were 
not able to provide reliable data on the epidemiological patterns of GNBI in the HSCT populations.     
The SIGNB survey, which includes about 64% of allo-HSCTs and 51% of auto-HSCTs 
performed in Italy in 2014, is a prospective study designed to critically assess not only the incidence 
during the pre-engraftment period but also the risk factors and the prognostic role of GNBI at four 
months from transplant. A valuable characteristic of this study is the availability of complete 
denominator data prospectively collected for consecutive patients who received transplant at each 
Centre. 
The overall pre-engraftment cumulative incidence of GNBI was 18.6% at 30 days from allo-HSCT 
and 10% at 20 days from auto-HSCT. E. coli, K. pneumoniae and P. aeruginosa were the most 
common isolates in both transplant procedures. In auto-HSCT patients, the resistance rates to third-
generation cephalosporins and to carbapenems in E. coli and K. pneumoniae and the MDR rate in P. 
aeruginosa were similar to those reported in the general Italian population by the EARS-net survey 
(14). Conversely, in allo-HSCT patients the rate of resistance was significantly higher.  Indeed, in 
allo-HSCT ceph-NS isolates were documented in about 40% of E. coli and 78% of K. pneumoniae, 
carba-NS isolates accounted for 53% of K. pneumoniae, and MDR was detected in about 36% of P. 
aeruginosa. While the resistance patterns of GNBI observed in auto-HSCT patients reflect the 
epidemiology of hospital acquired infections in standard-risk populations, in allo-HSCT the 
hospitalizations and exposition to multiple antibiotics courses during the pre-transplant period 
presumably justify the selection of microorganisms with reduced susceptibility phenotypes.   
We found that diagnosis of acute leukemia, a transplant performed from an HLA 
mismatched donor (both related and unrelated) and from cord blood, older age, and prolonged 
neutropenia were independent risk factors of pre-engraftment GNBI in allo-HSCT recipients. In the 
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setting of auto-HSCT a diagnosis of lymphoma, older age, and no antibacterial prophylaxis were 
significantly predictive of GNBI.   
Of interest is the different effect of fluoroquinolone prophylaxis in the two transplant 
populations since it  halved the rate of GNBI in auto-HSCT but had no significant impact on allo-
HSCT. If antibacterial prophylaxis continues to be indicated in neutropenic patients in an era of 
antibiotic resistance is a debated issue and some centers have already chosen to not administer it in 
view of the high rate of fluoroquinolones resistance and of the possible negative impact of 
prophylaxis in the selection of resistant intestinal flora (25-27).  Our data seem to show that in high 
risk patients with a history of antimicrobial pressure, as those submitted to allo-HSCT, 
fluoroquinolone prophylaxis is no more protective at least against GNBI, while low-risk, antibiotic 
treatment-free subjects, such as multiple myeloma patients who receive auto-HSCT immediately 
after a non-intensive remission induction therapy, still appear to benefit from selective intestinal 
decontamination  with fluoroquinolones during neutropenia.  Our data are in agreement with those 
reported in a recent retrospective, cohort study in neutropenic patients with multiple myeloma 
undergoing auto-HSCT in which levofloxacin prophylaxis was associated with a decreased risk of 
bloodstream infections and febrile neutropenia episodes (28). 
A pre-transplant infection in allo-HSCT and a colonization by resistant Gram-negative 
bacteria in both transplant procedures were highly predictive of a pre-engraftment infection by a 
pathogen with the same susceptibility phenotype (6). In view of the lack of a molecular 
characterization of the isolates we were not able to demonstrate if the same pathogen was 
responsible of the pre-transplant infection or colonization and of the  post-transplant GNBI; 
however, this correlation seems highly reliable in the majority of cases. Indeed, the high rate of 
early infection relapses (median 7 days from transplant), observed in allo-HSCT recipients with a 
pre-transplant infection by a resistant pathogen may suggest the failure of previous antibiotic 
treatment to eradicate the multiresistant infection, particularly by carba-NS pathogens.  
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Overall mortality at 4 months from transplant was 13.7% and 3% in allo-HSCT and auto-
HSCT, respectively. In addition to the well-known factors predicting poor outcome (acute 
leukemia, a previous auto-HSCT, a disease not in complete remission at the time of transplant, older 
age, prolonged pre-engraftment neutropenia,  acute-GVHD in allo-HSCT; a diagnosis of 
lymphoma, a prolonged  neutropenia during  the month preceding transplant, a disease not in 
complete remission at the time of transplant, prolonged pre engraftment neutropenia in auto-HSCT), 
GNBIs represented an independent prognostic factor in both populations  and a GNBI was the cause 
of death in 39.1% of allo-HSCT recipients who early died before the achievement of engraftment. 
However, the poor prognostic impact of GNBI was mainly related to infections by carba-NS 
enterobacteria and by P. aeruginosa, regardless of the susceptibility pattern, while the outcome of 
patients who developed an infection by carba-S enterobacteria was not significantly different from 
that of patients who did not experience any GNBI (29).  
In conclusion, our study identifies incidence and risk factors for GNBIs during the pre-
engraftment phase in a real life HSCT scenario. It confirms that the phenomenon of antimicrobial 
resistance is relevant in this high-risk population, particularly in allo-HSCT recipients, and 
dramatically impacts on the overall outcome of the patients both in auto-HSCT and allo-HSCT.  
Previous infectious history and colonization monitoring represent major indicators of the GNBI risk 
during the pre-engraftment phase.  The results of the present study may be useful to identify the 
sub-populations of transplant recipients who might benefit from targeted antibiotic treatments and 
underline the crucial importance of the continuous epidemiology monitoring in the definition of 
appropriate infection-control strategies in high-risk hematologic populations. 
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Table 1. Characteristics of patients  at transplant. 
Characteristic Allo-HSCT  (n = 1,118) Auto-HSCT (n= 1,625) 
Age, median years (range)  44 (1-72) 56 (1-75) 
Pediatric patients (age < 18 years) n. (%) 224 (20) 92 (5.7) 
Male sex n (%) 652 (58.3) 958 (58.9) 
Underlying disease: n. (%) 
Acute myeloid leukemia 
Acute lymphoid leukemia 
Other acute leukemias 
Myelodisplastic syndromes 
Chronic myeloproliferative  
Non Hodgkin’s lymphoma 
Hodgkin’s lymphoma 
Chronic lymphoid leukemia 
Multiple myeloma, plasmacellular leukemia, amyloidosis 
Aplastic anemia 
Hemoglobinopaties 
Solid tumors 
Other diseases 
 
420 
205 
6 
96 
64 
99 
66 
14 
59 
34 
28 
4 
23 
 
47 
15 
/ 
1 
2 
432 
168 
3 
846 
/ 
/ 
88 
23 
Phase of the underlying disease at transplant: n. (%) 
   Malignancies in complete remission 
   Malignancies not in complete  remission/active 
   Non malignant stable/ chronic diseases  
 
617 
416 
85 
 
668 
934 
23 
Previous hematopoietic stem cell transplant: n. (%) 
  Autologous alone 
  Allogeneic  alone 
  Autologous and Allogeneic 
 
204 
90  
15 
 
343 
2 
1 
Donor type: n. (%) 
HLA Matched related 
HLA MisMatched related* 
HLA Matched Unrelated volunteer 
HLA MisMatched Unrelated volunteer 
Unrelated cord blood 
 
296 
352 
295 
145 
30 
 
/ 
/ 
/ 
/ 
/ 
Stem cell source: n. (%) 
Bone Marrow 
Peripheral blood 
Cord blood 
 
476 
612 
30 
 
9 
1616 
/ 
Pretransplantation conditioning: n.(%) 
Myeloablative 
Reduced intensity 
Non myeloablative 
 
826 
251 
41 
 
1472 
32 
121 
T cell depletion 
 No 
 Yes in vivo (ATG or Alemtuzumab) 
 Yes ex vivo (graft manipulation) 
 
636 
386 
96 
 
1625 
/ 
/ 
Prolonged neutropenia during the month  before transplant 
(PMN <500/mmc for at least 7 days) 
219 82 
Rituximab therapy before autologous transplant NA 367 
Antibacterial prophylaxis during engraftment 
No 
Yes 
 
141 
977 
 
214 
1411 
 
* The 352 transplants from HLA MisMatched related donors included 311  haploidentical transplants  
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Table 2. Infections documented before engraftment 
 Allo-HSCT 
(n=1,118) 
Auto-HSCT 
(n=1,625) 
No fever, no infection, n. of patients (%) 329 (29.5) 755 (46.5) 
Fever of unknown origin only, n. of patients (%) 395 (35.3) 472 (29.0) 
Clinically documented infections, n of episodes/ n. of patients (%) 
- Pneumonia,  
- Skin infections,  
- Gastrointestinal tract,  
- Other,  
68/67 (6.0) 
39/39 (3.5) 
14/14 (1.2) 
6/6 (0.5) 
10/9 (0.8) 
87/85 (5.2) 
53/53 (3.3) 
12/12 (0.7) 
20/18 (1.1) 
2/2 (0.1) 
Microbiologically documented infections, n of episodes/ n. of patients (%) 
- Gram negative bacteria  
- Gram positive bacteria  
- Fungi  
- Viral diseases  
412/331 (30.1) 
  157/148 (13.2) 
209/193 (17.3) 
24/24 (2.1) 
22/22 (2.0) 
355/320 (19.2) 
    162/157 (9.7) 
182/172 (10.6) 
9/9 (0.5) 
2/2 (0.1) 
 
 
 
Table 3. Distribution of Gram-negative species and antimicrobial susceptibility patterns 
 
Pathogen and resistance pattern Allo-HSCT (n=157) Auto-ASCT (n=162) 
Escherichia coli, total n (%) 
    Ceph-S, Carba-S, n (% of E. coli) 
    Ceph-NS, Carba-S, n (% of E. coli) 
    Ceph-NS, Carba-NS, n (% of E .coli) 
78 (49.7) 
47 (60.3) 
30 (38.5) 
1 (1.3) 
94 (58.0) 
64 (68.1) 
30 (31.9) 
0 
Klebsiella pneumoniae, total n (%)  
    Ceph-S, Carba-S, n. (% of K. pneumoniae) 
    Ceph-NS, Carba-S,  n. (% of K. pneumoniae)   
    Ceph-NS, Carba-NS, n. (% of K. pneumoniae) 
32 (20.4) 
7 (21.9) 
8 (25.0) 
17 (53.1) 
25 (15.4) 
8 (32.0) 
10 (40.0) 
7 (28.0) 
Other enterobacteriaceae, total n (%) 
    Ceph-S, Carba-S, n. (% of other enterobacteriaceae) 
    Ceph-NS, Carba-S , (% of other enterobacteriaceae) 
    Ceph-NS, Carba-NS, (% of other enterobacteriaceae) 
10 (6.4) a 
9 890.0) 
0  
1 (10.0) 
12 (7.4) b 
12 (100) 
0 
0 
Pseudomonas aeruginosa, total n (%) 
   Non-MDR P. aeruginosa, (% of P. aeruginosa) 
   MDR-P. aeruginosa, (% of P. aeruginosa) 
22 (14.6) 
14 (63.6) 
8 (36.4) 
13 (8.0) 
12 (92.3) 
1 (7.7) 
Other Gram negative bacteria, total n (%) 
   No-MDR , (% of other Gram negative) 
   MDR, (% of other Gram negative) 
15 (9.5) c 
11 (73.3) 
4 (26.7) 
18 (11.1) d 
16 (88.9) 
2 (11.1) 
Ceph-S: susceptible to third generation cefhalosporins; Carba-S: susceptible to carbapenems, defined as a 
MIC  for imipenem, meropenem and ertapenem < 1 mg/L; Carba-R: resistant to carbapenems, defined 
as a MIC  for imipenem and/or meropenem and/or ertapenem > 1 mg/L; MDR= multi drug resistant, 
resistance to at least three of the following antibiotics: ciprofloxacin, amikacin,  piperacillina-tazobactam, 
ceftazidime and meropenem or imipenem 
 a: Enterobacter spp, 6 cases; Klebsiella oxytoca, 2 cases; Proteus mirabilis, 1 case; Serratia marcescens, 1 
case. 
b: Enterobacter spp, 5 cases; Proteus mirabilis, 3 cases; Morganella morganii, 2 cases; Serratia marcescens, 1 
case; Yersinia enterocolitica, 1 case  
c: Stenotrophomonas maltophilia, 4 cases; Acinetobacter spp, 3 cases; Pseudomonas spp, 4 cases; 
Capnocytophaga spp, 2 cases; Rhizobium radiobacter, Citrobacter sp, 1 case each. 
d: Acinetobacter spp, 6 cases; Campylobacter jejunii, 4 cases; Capnocytophaga spp, 2 cases; Bacteroides 
fragilis, Citrobacter sp, Fusobacterium sp, Sphingomonas sp, Pseudomonan sp 1, Stenotrophomonas 
maltophilia, one  case each 
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Table 4. Cumulative Incidence and risk factors for GNBIs during the engraftment period after allo-HSCT 
according to the demographic, underlying disease and transplant variables. 
Variables 
Univariate analysis Multivariate analysis 
HR (95% CI) P HR (95% CI) P 
Gender 
Male 1.00    
Female 1.023 (0.74-1.42) 0.87   
Age (increased by 10 years) 1.19 (1.09-6.14) <.0001 1.15 (1.05-1.25) 0.016 
Underlying disease 
Acute leukemia 1.00    
Other diseases 0.70 (0.50-0.97) 0.03 0.64 (0.46-0.89) 0.009 
Phase of the 
underlying disease at 
transplant 
Complete remission 1.00    
No complete remission 1.13 (0.82-1.56) 0.46   
Previous auto-HSCT 
No 1.00 0.95   
Yes 0.99 (0.66-1.48)    
Previous allo-HSCT 
No 1.00    
Yes 1.11 (0.67-1.85) 0.69   
Pre-transplant 
neutropenia 
No 1.00    
Yes 1.06 (0.71-1.56) 0.79   
Stem Cell Source_ 
Peripheral blood 1.00    
Bone marrow 1.71 (1.23-2.40) 0.001   
Cord blood 2.76 (1.24-6.13) 0.013   
Donor type 
Matched related 1.00    
Mismatched related 3.73 (2.17-6.42) <.0001 3.74 (2.15-6.50) <.0001 
Matched Unrelated 
volunter 
1.96 (1.07-3.58) 0.03 1.64 (0.87-3.10) 0.12 
Mismatched unrelated 
volunter 
3.49 (1.87-6.51) <.0001 2.91 (1.50-5.64) 0.0015 
Cord blood 5.11 (20.7-12.65) 0.0004 3.77 (1.50-9.45) 0.005 
Conditioning_regimen 
Myeloablative 1.00    
Non myeloablative/ 
reduced intensity 
1.73 (1.25-2.41) 0.001   
T cell depletion 
No 1.00    
Yes, ATG in vivo 1.08 (0.77-1.51) 0.67   
Yes, manipulation ex vivo 0.16 (0.04-0.63) 0.009   
Antibacterial 
prophylaxis 
No 1.00    
Yes 0.77 (0.49-1.22) 0.27   
Acute GVHD during 
engraftment 
Grade 0-I 1.00    
Grade II-IV 1.13 (0.29-4.39) 0.86   
Days of pre-
engraftment 
neutropenia 
PMN <500/cmm 1.02 (1.01-1.03) <.0001   
PMN <100/cmm 1.03 81.02-1.04) <.0001 1.02 (1.01-1.03) 0.0004 
Mucositis 
CTC Grade 0-I 1.00    
CTC Grade II-IV 1.07 (0.77-1.49) 0.68   
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Table 5. Probability of mortality at 4 months from allo-HSCT 
 Univariate Multivariate 
HR (95% CI) P HR (95% CI) P 
female vs male 0.82(0.59-1.14) 0.24   
Age (increased by 10 years) 1.15(1.06-1.25) 0.0014 1.10 (1.01-1.21) 0.026 
Underlying disease, no acute leukemia vs acute leukemia 0.81(0.59-1.12) 0.21 0.42 (0.28-0.62) <.0001 
Phase of the underlying disease at transplant , no CR vs CR  1.82(1.32-2.51) 0.0003 2.18 (1.49-3.19) <.0001 
Prior auto-HSCT, yes vs no 1.43 (0.10-2.06) 0.051 1.76 (1.18-2.63) 0.006 
Prior allo-HSCT, yes vs no 1.60 (1.01-2.54) 0.045   
Pre-transplant neutropenia, yes vs no 1.34 (0.93-1.94) 0.12   
Stem cell source  
Bone marrow vs Peripheral  
Cord blood vs Peripheral 
 
1.10(0.79-1.53) 
1.93(0.89-4.19) 
 
0.55 
0.09 
  
Donor type 
Mismatched related vs matched related 
Matched Unrelated volunteer vs matched related 
Mismatched unrelated volunteer vs matched related 
Cord blood vs matched related 
 
1.93(1.25-2.97) 
1.19(0.73-1.93) 
1.11(0.60-2.03) 
2.51 (1.10-5.71) 
 
0.003 
0.48 
0.74 
0.028 
  
Non Myeloablative/RIC vs myeloablative conditioning 1.55(1.11-2.16) 0.01   
T cell depletion  
In vivo ATG vs no T cell depletion 
Ex vivo manipulation vs no T cell depletion 
 
1.04 (0.74-1.46) 
1.0 (0.26-1.79) 
 
0.82 
0.99 
  
Antibacterial prophylaxis, yes vs no 0.76 (0.49-1.17) 0.21   
Mucositis, CTC grade II-IV vs CTC grade 0-I 0.94 (0.68-1.31) 0.73   
Days of pre engraftment neutropenia,  
ANC < 500/cmm 
ANC < 100/cmm 
 
1.02 (1.01-1.04) 
1.03 (1.02-1.04) 
 
<.0001 
<.0001 
 
 
1.03(1.01-1.04) 
 
 
<.0001 
Acute GVHD, grade II-IV vs grade 0-I 2.07 (1.17-3.65) 0.01 2.16 (1.21-3.84) 0.009 
Gram negative bacterial infection, yes vs no 2.86 (1.97-4.05) <.0001 2.08 (1.43-3.04) 0.0001 
ATG:	  anti	  thymocyte	  globulin;	  	  CTC=	  Common	  Toxicity	  Criteria	  ANC=	  absolute	  neutrophil	  count;	  HSCT=	  
hematopoietic	  stem	  cell	  transplant;	  HR=	  hazard	  ratio;	  CI=	  Confidential	  Interval;	  CR=complete	  remission;	  
AL=	  acute	  leukemia;	  	  GVHD=	  graft	  versus	  host	  disease;	  	  
RIC=	  reduced	  intensity	  conditioning
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Table 6. Cumulative Incidence and risk factors for GNBIs during the engraftment period after auto-HSCT 
according to the demographic, underlying disease and transplant variables 
Variables 
Univariate analysis Multivariate analysis 
HR (95% CI) P HR (95% CI) P 
Gender 
Male 1.00    
Female 10.9 (0.78-1.50) 0.57   
Age (increased by 10 years) 1.09 (0.99-1.21) 0.09 1.18 (1.05-1.33) 0.006 
Underlying disease 
Multiple myeloma 1.00    
Lymphoma 1.50 (1.08-2.10) 0.015 1.84 (1.31-2.61) 0.0005 
Acute leukemia 1.58 (0.77-3.24) 0.21 1.69 (0.82-3.50) 0.15 
Other diseases 1.09 (0.56-2.11) 0.80 2.08 (0.93-4.64) 0.07 
Phase of the 
underlying disease at 
transplant 
Complete remission 1.00    
No complete remission 1.58 (0.84-1.60) 0.37   
Previous auto-HSCT 
No 1.00    
Yes 0.85 (0.60-1.27) 0.43   
Pre transplant 
rituximab 
No 1.00    
Yes 1.48 (1.05-2.08) 0.03   
Pre-transplant 
neutropenia 
No 1.00    
Yes 1 (0.49-2.03) 1   
Antibacterial 
prophylaxis 
No 1.00    
Yes 0.48 (0.33-0.68) 0.0001 0.46 (0.32-0.68) <.0001 
Days of pre-
engraftment 
neutropenia 
PMN <500/cmm 1.03 (1.004-1.048) 0.02   
PMN <100/cmm 1.03 (1.007-1.05) 0.01   
Mucositis 
CTC Grade 0-I 1.00    
CTC Grade II-IV 1.07 (0.78-1.47) 0.65   
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Table	  7.	  Probability	  of	  mortality	  at	  4	  months	  from	  auto-­‐HSCT	  
 Univariate Multivariate 
HR (95% CI) P HR (95% CI) P 
female vs male 0.78 (0.43-1.41) 0.4   
Age (increased by 10 years) 0.99 (0.83-1.18) 0.9   
Underlying disease,  
 Multiple myeloma 
 Lymphoma 
 Acute leukemia 
 Other diseases 
 
1.00 
5.1 (2.44-10.7) 
3.01 (0.65-13.94) 
4.1 (1.38-12.3) 
 
 
<.0001 
0.16 
0.01 
 
 
5.07 (2.35-10.9) 
 
 
 
<.0001 
 
Phase of the underlying disease at transplant, no CR vs 
CR  
3.55 (1.7-7.6) 0.001 4.8 (2.23-10.4) <.0001 
Prior auto-SCT, yes vs no 0.86 (0.41-1.77) 0.68   
Pre-transplant rituximab, yes vs no 2.9 (1.7-5.2) 0.0002   
Pre-transplant neutropenia, yes vs no 5.2 (2.6-10.5) <.0001 3.39 (1.62-7.12) 0.001 
Antibacterial prophylaxis, yes vs no 1.31 (0.52-3.31) 0.57   
Mucositis, CTC grade II-IV vs CTC grade 0-I 1.36 (0.76-2.44) 0.30   
Days of pre engraftment neutropenia,  
PMN < 500/cmm 
PMN < 100/cmm 
 
1.09 (1.06-1.12) 
1.09 (1.07-1.12) 
 
<.0001 
<.0001 
 
 
1.08 (1.04-1.12) 
 
 
<.0001 
Gram negative bacterial infection, yes vs no 2.93 (1.49-5.74) 0.0018 2.53 (1.28-50.) 0.008 
CR=complete	  remission;	  AL=	  acute	  leukemiaGVHD=	  graft	  versus	  host	  disease;	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Figure	  1.	  Cumulative	  incidence	  curve	  for	  Gram	  Negative	  Bacterial	  Infection	  among	  allo-­‐HSCT	  (A)	  
and	  auto-­‐HSCT	  (B)	  recipients	  in	  the	  GITMO	  epidemiological	  survey.	  
	  
Figure	  2.	  	  Risk	  of	  pre-­‐engraftment	  Gram	  Negative	  Bacterial	  Infection	  recurrence	  according	  to	  pre-­‐
transplant	  infection	  by	  the	  same	  species	  with	  the	  same	  susceptibility	  phenotype	  in	  allo-­‐HSCT.	  The	  
risk	  was	  calculated	  only	  for	  species	  with	  significant	  rate	  of	  pre-­‐transplant	  infection.	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Figure	  3.	  Risk	  of	  pre-­‐engraftment	  Gram	  Negative	  Bacterial	  Infection	  according	  to	  colonization	  by	  
resistant	  gram	  negative	  bacteria	  in	  allo-­‐HSCT	  (A)	  and	  auto-­‐HSCT	  (B)	  patients.	  The	  risk	  was	  
calculated	  only	  for	  species	  with	  significant	  rate	  of	  colonization.	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Figure	  4.	  Probability	  of	  survival	  at	  4	  month	  from	  allo-­‐HSCT	  according	  to	  the	  development	  of	  a	  pre-­‐
engraftment	  Gram	  Negative	  Bacterial	  Infection	  (GNBI)	  by	  different	  species.	  Survival	  was	  calculated	  
only	  for	  species	  with	  significant	  rate	  of	  infection.	  
	  
	  
